Table 1. Demographic and clinical information for eligible patients diagnosed with Intrahepatic Cholangiocarcinoma within the National Cancer Database, 2004–2012.
Clinical T, N, and M stages are defined according to 8th edition of the AJCC Cancer Staging Manual. Statistical comparison is made within the cohort of patients undergoing curative-intent resection within 90 days of diagnosis, between the patients undergoing nodal examination (n=1,132) and those without nodal examination (n=868). cT3 disease is blank, as the 8th edition definition does not align with the 6th and 7th editions used for this cohort in the NCDB.
| Curative-Intent Resection Within 90 Days of Diagnosis |
|||||||
|---|---|---|---|---|---|---|---|
| No Lymph Nodes Examined | Lymph Nodes Examined | p | |||||
| n or median | % or IQR | n or median | % or IQR | n or median | % or IQR | ||
| n | 2,871 | 868 | 1,132 | ||||
| Age | 63 years | 54 – 71 | 64 years | 56 – 72 | 60 years | 53 – 70 | <0.001 |
| Female | 1,535 | 53.5% | 431 | 49.7% | 655 | 57.9% | <0.001 |
| Charlson Comorbidity Index | <0.001 | ||||||
| 0 | 1,983 | 69.1% | 557 | 64.2% | 824 | 72.8% | |
| 1 | 605 | 21.1% | 210 | 24.2% | 210 | 18.6% | |
| ≥ 2 | 283 | 9.9% | 101 | 11.6% | 98 | 8.7% | |
| Race/Ethnicity | 0.011 | ||||||
| White | 2,219 | 77.3% | 647 | 74.5% | 915 | 80.8% | |
| Black | 208 | 7.2% | 70 | 8.1% | 62 | 5.5% | |
| Hispanic/Latino | 171 | 6.0% | 54 | 6.2% | 59 | 5.2% | |
| Asian | 152 | 5.3% | 61 | 7.0% | 49 | 4.3% | |
| Other | 61 | 2.1% | 15 | 1.7% | 21 | 1.9% | |
| Missing/Unknown | 60 | 2.1% | 21 | 2.4% | 26 | 2.3% | |
| Insurance Status | 0.078 | ||||||
| Private | 1,316 | 45.8% | 371 | 42.7% | 555 | 49.0% | |
| Medicare | 1,160 | 40.4% | 386 | 44.5% | 456 | 40.3% | |
| Medicaid/Other Government | 225 | 7.8% | 66 | 7.6% | 73 | 6.4% | |
| None | 73 | 2.5% | 21 | 2.4% | 25 | 2.2% | |
| Missing/Unknown | 97 | 3.4% | 24 | 2.8% | 23 | 2.0% | |
| Treating Facility | 0.261 | ||||||
| Academic | 1,954 | 68.1% | 583 | 67.2% | 787 | 69.5% | |
| Other | 917 | 31.9% | 285 | 32.8% | 345 | 30.5% | |
| Clinical T Stage | <0.001 | ||||||
| T1a/b | 728 | 25.4% | 283 | 32.6% | 269 | 23.8% | |
| T2 | 699 | 24.3% | 194 | 22.4% | 262 | 23.1% | |
| T3 | - | - | - | - | - | - | |
| T4 | 165 | 5.7% | 29 | 3.3% | 57 | 5.0% | |
| Unknown or T0 | 1,267 | 44.1% | 362 | 41.7% | 544 | 48.1% | |
| Clinical N Stage | <0.001 | ||||||
| 0 | 1,504 | 52.4% | 530 | 61.1% | 549 | 48.5% | |
| 1 | 240 | 8.4% | 19 | 2.2% | 120 | 10.6% | |
| Missing/Unknown | 1,127 | 39.3% | 319 | 36.8% | 463 | 40.9% | |
| Clinical M Stage | |||||||
| 0 | 2,463 | 85.8% | 833 | 96.0% | 1083 | 95.7% | 0.921 |
| 1 | 181 | 6.3% | 34 | 3.9% | 48 | 4.2% | |
| Missing/Unknown | 308 | 10.7% | 1 | 0.1% | 1 | 0.1% | |
| Tumor Size | 5.5 cm | 3.5 – 8.4 | 5.1 cm | 3.5 – 8.0 | 6.0 cm | 3.5 – 8.6 | 0.009 |